BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 17013540)

  • 1. Loss of heterozygosity on chromosomes 2p, 3p, 18q21.3 and 11p15.5 as a poor prognostic factor in stage II and III (FIGO) cervical cancer treated by radiotherapy.
    Kozlowski L; Filipowski T; Rucinska M; Pepinski W; Janica J; Skawronska M; Poznanski J; Wojtukiewicz MZ
    Neoplasma; 2006; 53(5):440-3. PubMed ID: 17013540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer.
    Harima Y; Harima K; Sawada S; Tanaka Y; Arita S; Ohnishi T
    Clin Cancer Res; 2000 Mar; 6(3):1079-85. PubMed ID: 10741737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability is a late event in the carcinogenesis of uterine cervical cancer.
    Nishimura M; Furumoto H; Kato T; Kamada M; Aono T
    Gynecol Oncol; 2000 Nov; 79(2):201-6. PubMed ID: 11063644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of genetic instabilities on chromosome loci 3, 6, 11, and 18 in human cervical carcinoma].
    Zhao M; Wu XX
    Ai Zheng; 2002 Jun; 21(6):640-3. PubMed ID: 12452066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
    Xu XF; Tang PZ; Cheng SJ
    Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High grade sarcomas are associated with microsatellite instability (chromosom 12) and loss of heterozygosity (chromosom 2).
    Rucińska M; Kozłowski L; Pepiński W; Skawrońska M; Janica J; Wojtukiewic MZ
    Med Sci Monit; 2005 Feb; 11(2):BR65-8. PubMed ID: 15668629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma.
    el-Naggar AK; Hurr K; Batsakis JG; Luna MA; Goepfert H; Huff V
    Cancer Res; 1995 Jun; 55(12):2656-9. PubMed ID: 7780981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer.
    Cheung TH; Lo KW; Yim SF; Poon CS; Cheung AY; Chung TK; Wong YF
    Gynecol Oncol; 2005 Feb; 96(2):510-5. PubMed ID: 15661244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity in laryngeal cancer.
    Rogowski M; Walenczak I; Pepiński W; Skawrońska M; Sieśkiewicz A; Klatka J
    Rocz Akad Med Bialymst; 2004; 49():262-4. PubMed ID: 15631354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer.
    Sánchez-Céspedes M; Rosell R; Pifarré A; López-Cabrerizo MP; Barnadas A; Sánchez JJ; Lorenzo JC; Abad A; Monzó M; Navas-Palacios JJ
    Clin Cancer Res; 1997 Jul; 3(7):1229-35. PubMed ID: 9815804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma.
    Cheung TH; Chung TK; Poon CS; Hampton GM; Wang VW; Wong YF
    Cancer; 1999 Oct; 86(7):1294-8. PubMed ID: 10506716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detailed deletion mapping of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis.
    Xu XF; Gao YN; Cheng SJ
    Chin Med J (Engl); 2004 Aug; 117(8):1204-9. PubMed ID: 15361296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of heterozygosity loss in chromosome 3p in non-microcytic bronchogenic carcinoma].
    Maestro ML; Izquierdo L; Sánchez-Pernaute A; Sanz Casla MT; González S; Torres A; del Barco V; Gómez A; Pérez Aguirre E; Balibrea JL
    Med Clin (Barc); 1999 Apr; 112(14):527-9. PubMed ID: 10363238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of allelic imbalances on chromosome 3p in nasopharyngeal carcinoma in Tunisia: high frequency of microsatellite instability in patients with early-onset of the disease.
    Trimeche M; Braham H; Ziadi S; Amara K; Hachana M; Korbi S
    Oral Oncol; 2008 Aug; 44(8):775-83. PubMed ID: 18206419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity analysis in uterine cervical adenocarcinoma.
    Miyai K; Furugen Y; Matsumoto T; Iwabuchi K; Hirose S; Kinoshita K; Fujii H
    Gynecol Oncol; 2004 Jul; 94(1):115-20. PubMed ID: 15262128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations.
    Boyle JO; Lonardo F; Chang JH; Klimstra D; Rusch V; Dmitrovsky E
    Clin Cancer Res; 2001 Feb; 7(2):259-66. PubMed ID: 11234877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite allelotyping of chinese nasopharyngeal carcinomas.
    Lung ML; Choi CV; Kong H; Yuen PW; Kwong D; Sham J; Wei WI
    Anticancer Res; 2001; 21(4B):3081-4. PubMed ID: 11712814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication.
    Mitsudomi T; Oyama T; Nishida K; Ogami A; Osaki T; Sugio K; Yasumoto K; Sugimachi K; Gazdar AF
    Clin Cancer Res; 1996 Jul; 2(7):1185-9. PubMed ID: 9816286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy.
    Guo Z; Yamaguchi K; Sanchez-Cespedes M; Westra WH; Koch WM; Sidransky D
    Clin Cancer Res; 2001 Jul; 7(7):1963-8. PubMed ID: 11448911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.
    Pang JZ; Qin LX; Ren N; Hei ZY; Ye QH; Jia WD; Sun BS; Lin GL; Liu DY; Liu YK; Tang ZY
    Clin Cancer Res; 2007 Dec; 13(24):7363-9. PubMed ID: 18094418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.